Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Evidence-Based Health Reporting

The legacy context of general health and science information has long provided foundational knowledge on disease transmission, public health responses, and clinical outcomes. This heritage includes comprehensive documentation of outbreaks such as the Ebola virus epidemic in West Africa, where case counts, geographic spread, and mortality data were systematically reported. Such frameworks established rigorous standards for evaluating health risks and communicating evidence to diverse audiences. Transitioning from this broad informational base to a more focused clinical concern requires a shift in perspective—from population-level epidemiology to individual patient exposure histories. In the domain of mass production, where large-scale manufacturing processes involve chemical compounds, the same principles of evidence review apply. Specifically, the clinical consideration of bisphosphonate therapy, such as Fosamax, and its potential association with osteonecrosis of the jaw emerges as a targeted inquiry. This pivot moves from general health literacy toward a specific exposure scenario: the long-term use of medications in patient populations. The occupational exposure concern here is not about workplace hazards but about the clinical exposure pathway—how sustained pharmaceutical intake may correlate with adverse outcomes. By maintaining the neutral, evidence-based approach of legacy health reporting, this transition reframes the question from broad disease surveillance to a precise review of causation in a therapeutic context.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The diagnosis is primarily clinical, based on the presence of exposed bone in the jaw that persists for more than eight weeks in the absence of prior radiation therapy. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique susceptibility of the jawbone to such complications, likely due to its high remodeling rate and vascular anatomy.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, its potent antiresorptive action can suppress normal bone turnover, which is hypothesized to contribute to ONJ pathogenesis. The time to onset of ONJ symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that early symptoms may not be specific to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate, indicating a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways and Risk Factors

The exact mechanism by which Fosamax causes ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates accumulate in bone, particularly at sites of high turnover such as the jaw, and inhibit osteoclast activity. This suppression of bone remodeling may impair the ability to repair microdamage and maintain bone viability, leading to necrosis. Additionally, bisphosphonates have anti-angiogenic properties that could reduce blood supply to the jawbone, further contributing to tissue death. The multiscale characterization of jawbone tissue has highlighted the importance of understanding these local responses to bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

The prescribing information for Fosamax includes a warning under Section 5.4, 'Osteonecrosis of the Jaw,' which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). While these warnings are present, the adequacy of their communication to patients and healthcare providers has been a subject of debate. The label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of clarity may contribute to prolonged exposure and increased risk. Establishing causation between Fosamax and ONJ in individual patients requires careful evaluation of temporal relationship, alternative causes, and biological plausibility. The time to onset of symptoms can vary from one day to several months after starting the drug, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Recurrence upon rechallenge further supports a causal link. However, ONJ can also occur spontaneously in the absence of bisphosphonate use, and many affected patients have additional risk factors such as dental procedures, cancer, or corticosteroid use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Therefore, a comprehensive assessment of each patient's medical history and risk profile is necessary.

Timeline Between Exposure and Documented Harm

The timeline between Fosamax exposure and ONJ development is variable. Symptoms may appear as early as one day after starting the drug or may take several months to manifest (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk appears to increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients on long-term therapy, particularly those undergoing invasive dental procedures, the risk of ONJ is elevated. Discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring such procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures, cancer, or prolonged use. The prescribing information includes warnings, but the variable onset and multifactorial nature of ONJ require careful patient monitoring and risk assessment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

The exact mechanism is not fully understood, but Fosamax suppresses bone remodeling by inhibiting osteoclast activity, which may impair repair of microdamage and lead to necrosis. It also has anti-angiogenic properties that could reduce blood supply to the jawbone (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.